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doi:10.1016/j.ejvs.2009.02.020Abstract Objectives: Thrombomodulatory factors have been implicated in plaque instability.
The aim was to examine the relationship between thrombomodulatory gene expression, timing
of clinical events and plaque histology.
Design of Study: Plaques were obtained from 40 consecutive patients undergoing carotid endar-
terectomy and divided into three groups (group 1, early symptomatic, within 1 month; group 2,
late symptomatic, 1e6 months and group 3, asymptomatic). Total RNA was isolated to deter-
mine the expression of tissue plasminogen activator (t-PA), urokinase plasminogen activator
(u-PA), plasminogen activator inhibtor-1 (PAI-1), tissue factor (TF), tissue factor pathway inhib-
itor (TFPI), thrombomodulin (TM), CD68 and vascular endothelial-cadherin (VE-Cadherin).
Results: Expression of t-PA, PAI-1, TF, TFPI, TM, CD68 and VE-cadherin were significantly
increased in the early symptomatic group (pZ 0.019, 0.028, 0.018, 0.025, 0.038, 0.016 and
0.027 respectively), but the level of gene expression in the late symptomatic group was indis-
tinguishable from the asymptomatic group. The incidence of plaque rupture and intraplaque
haemorrhage was significantly increased in the early symptomatic groups (58% versus 18%/
18% group 2/3, and 55% versus 6%/9% respectively, p< 0.05 for both).
Conclusions: Expression of thrombomodulatory genes is increased in unstable plaques, though
levels after 1 month are comparable to asymptomatic plaques. This transient rise may influence
plaque instability, and rapid resolution mirrors the clinical reduction in risk of further thrombo-
embolic events.
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Surgery. All rights reserved.t George’s, Vascular Institute, St James’ Wing, St Georges Healthcare NHS Trust, Blackshaw Road,
725 3205; fax: þ44 208 725 3475.
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Carotid Expression of Thrombomodulatory Factors 21Introduction Patients were divided into three groups according to timingFollowing an acute cerebral ischaemic episode attributable
to carotid atherosclerosis, patients are at the highest risk of
a further event in the subsequent 2 weeks; 12% of patients
awaiting carotid endarterectomy will have a second clinical
event within a month.1 This period of increased thrombo-
embolic risk is associated with transient carotid plaque
instability, involving increased proteolysis, inflammation
and plaque disruption.1e3 After 1 month, the risk of further
ischaemic complications diminishes, associated with reso-
lution of the inflammatory and proteolytic mechanisms.
The role of thrombomodulatory factors is complex and
poorly understood. Although the expression of haemostatic
factors has been investigated in unstable coronary plaqu-
es3e6 the relationship in carotid plaques is not documented,
with no data regarding changes in expression following the
onset of symptoms. Plaque disruption, whether due to
superficial erosion of the endothelium, intraplaque hae-
morrhage or intimal cap fracture, leads to activation of
coagulation and thrombus formation.1e3 Haemostatic
factors have been shown to play an important role in the
aetiology of the unstable plaque, both directly and indi-
rectly through influencing smooth muscle proliferation and
local proteolysis.4e6 Elevated expression of pro-thrombotic
mediators at the sites of plaque disruption could influence
clinical events through promotion of unstable thrombus on
the surface of the plaque.
The aim of this study was to investigate changes in
carotid plaque expression of thrombomodulatory genes
during the high risk period immediately after the onset of
clinical ischaemic events. Plaques were analysed histolog-
ically and total RNA isolated to determine the level of gene
expression for tissue plasminogen activator (t-PA), uroki-
nase plasminogen activator (u-PA), plasminogen activator
inhibtor-1 (PAI-1), tissue factor (TF), tissue factor pathway
inhibitor (TFPI), thrombomodulin (TM), markers of acti-
vated macrophages (CD68) and, vascular endothelial-cad-
herin (VE-Cadherin).
Tissue factor represents the most potent pro-thrombo-
genic factor identified in plaques. Tissue factor expression
of is strongly induced in activated macrophages and
T-lymphocytes. Through binding to factor VIIa, tissue factor
directly activates the coagulation cascade. Fibrinolysis is
activated by the 2 physiological plasminogen activators,
t-PA and u-PA. Tissue-type plasminogen activator (t-PA) is
a key enzyme mediating plasminogen to plasmin conver-
sion. VE-Cadherin is a calcium dependant cell adhesion
molecule implicated in atherosclerosis, expressed by
endothelial cells associated with neovascularisation, and
a marker of endothelial activation.Materials and Methods
Collection of specimens
This study was approved by the Local Research Ethics
Committee and written informed consent was obtained
from each patient. Forty consecutive patients admitted for
carotid endarterectomy were recruited to the study.of clinical events (group 1, early symptomatic e a clinical
event less than 1 month before surgery; group 2, late
symptomatic e a clinical event 1e6 months before surgery
and group 3, asymptomatic e event free for >6 months
prior to surgery). Vascular risk factors were assessed, along
with a detailed drug history. Smoking includes past or
present history of smoking; ischaemic heart disease (IHD),
past history of myocardial infarction or angina requiring
treatment; hypertension, high blood pressure requiring
treatment; diabetes, insulin or non-insulin dependent dia-
betes requiring treatment, including diet controlled;
hyperlipidaemia based on current medication and/or
random fasting lipid levels.
All patients had a neurological assessment for identi-
fication of residual neurological deficits. 11 patients had
suffered a stroke, 11 had amaurosis fugax, 4 had tran-
sient ischaemic attacks (TIAs) and 3 had symptoms
suggestive of cerebral hypo perfusion. Diagnosis and
decision to perform surgery are made by a multi-disci-
plinary team of stroke physicians, neuro-radiologists and
vascular surgeons.
All operations were performed with standard surgical
techniques and with minimal manipulation of the spec-
imen. Immediately following surgical removal, the carotid
plaques were immersed in RNA stabilising solution. The
samples were bisected longitudinally through the mid-line
of the most occlusive lesion or the most apparent lesion.
One half was processed for RNA isolation and the remaining
sample processed for frozen serial sectioning, histological
and immunohistochemical analysis.Quantitative Real Time-PCR
Total RNA extraction and cDNA synthesis
Tissue samples were ground to a fine powder in liquid
nitrogen and total RNA extracted from a maximum of 60 mg
of powdered tissue following the manufacturer’s protocol
(RNeasy Fibrous Tissue RNA extraction kit, Qiagen, UK).
Samples of high integrity were reverse transcribed using
high capacity cDNA archive kit (Applied Biosystems, UK).
Real time quantitative RT-PCR
The mRNA levels of candidate genes were determined by
Quantitative Real Time (QRT)-PCR using TaqMan probes
(Assays-on-Demand Gene Expression Products, Applied
Biosystems, UK), with the carboxyfluorescein fluorescent
dye 6-FAM as the 50-fluorophore and nonfluorescent
quencher (NFQ) at the 30-end of the probe.
QRT-PCR reaction mixtures for each sample were 50 ml,
containing 25 ml of 2 TaqMan Universal Master Mix (without
AmpErase UNG), 22.5 ml of cDNA template and 2.5 ml of
20 target assay mix. Each sample was run in triplicate and
for all reactions, negative controls were run with no
template present. QRT-PCR was carried out using an Mx4000
Multiplex Quantitative PCR System. The associated Mx4000
software was used to analyze the data and determine the
threshold count (Ct). Ct was determined for the target genes
Table 1 Clinical Risk factors for patients assigned to each
group based on symptom-free duration. There were no
significant differences between groups (p> 0.05 for all
groups)
Symptom Groups
Risk Factor/
Group
Early
Symptomatic
Late
Symptomatic
Asymptomatic
1 (nZ 12) 2 (nZ 17) 3 (nZ 11)
Age, median
(range)
70 (60e84) 69 (58e86) 72 (58e83)
Sex, male:
female
9:3 10:7 7:4
Smoking, n (%) 7 (58%) 13 (76%) 7 (64%)
IHD, n (%) 7 (58%) 4 (24%) 7 (64%)
Hypertension,
n (%)
7 (58%) 12 (71%) 8 (73%)
Diabetes, n (%) 1 (8%) 7 (41%) 5 (45%)
Hyperlipidaemia,
n (%)
8 (67%) 14 (82%) 10 (91%)
Statin use,
n (%)
10 (83%) 16 (94%) 10 (91%)
22 S. Sayed et al.and 18S ribosomal RNA (rRNA). 18S rRNA was chosen as the
endogenous control to which we normalised our specimens.
Preliminary validation experiments verified that the effi-
ciencies of target gene amplification and the efficiency of 18S
rRNA amplification to be approximately equal and therefore
validated that the target gene: 18S rRNA ratio can be
calculated using the Ct method. For each sample, Ct
target gene
and Ct
18S rRNA were determined, and CtZ Ct
target gene
Ct
18S rRNA. The relative level of target gene normalised to 18S
rRNA was determined by calculating: 2DCt.
Histology
Serial sections were cut (5 mm for standard stains (Hae-
matoxylin and eosin and elastic Van Geison), and 10 mm
sections for immunohistochemistry) from each carotid
plaque. Sections were then evaluated by an experienced
cardio-histopathologist (R.P.), blinded to the clinical find-
ings and identity of each patient. Four sections from each
plaque were examined at different levels for the presence
of plaque rupture, cap thinning, intraplaque haemorrhage,
and core necrosis. Intraplaque haemorrhage included
recent and aged haemorrhage as previously defined.7 Pla-
que rupture was recorded where there was a clear
connection between lipid core and lumen with a break in
the fibrous cap. Immunohistochemical staining was per-
formed for CD68, a marker of macrophage activation, but
no quantification of staining was performed, nor correlation
with CD68 gene expression.
Statistical Analysis
Quantitative RT-PCR results are expressed as median values
and interquartile ranges and compared by the Kruskale
Wallis ANOVA. Risk factors and individual histological
features were analysed by the chi-squared test. Manne
Whitney analysis was used to correlate gene expression
with histological findings. All analyses were performed
using SPSS (version 10 for Windows). Significance was
assumed with a p value of< 0.05 except for correlations
between gene expression and histological features, where
Bonferroni correction was applied.Table 2 Histological plaque characteristics of each of 3
symptom groups (analysed using KruskaleWallis ANOVA)
Symptom Groups: n (%)
Histological
Features
Early
Symptomatic
1 (nZ 12)
Late
Symptomatic
2 (nZ 17)
Asymptomatic
3 (nZ 11)
p
value
PR 7 (58) 3 (18) 2 (18) 0.03
IPH 7 (55) 1 (6) 1 (9) 0.002
PCT 8 (66) 10 (59) 5 (54) 0.21
PN 8 (66) 10 (59) 6 (54) 0.21
PR, plaque rupture; IPH, intraplaque haemorrhage; PCT, plaque
cap thinning; PN, plaque necrosis; NSD, no significant
difference.Results
Patient demographics
Patients were all assessed pre-operatively. There were 26
men and 14 women with a median age of 71years (range
58e86 years). All patients had a significant carotid artery
stenosis based on standard duplex and MRA criteria (>70%).
In addition all patients were on long term aspirin therapy
and there was no difference between the three groups in
the use of other medications including lipid-lowering
agents. No patient had a documented thrombophilia or
coagulopathy. There were no significant differences
between the major demographic features or cardiovascular
risk factors between the three groups of patients (x2 test,
p> 0.05) (Table 1).Histological and Immunohistochemical Examination
Significantly more plaques in Group 1 (early symptomatic)
demonstrated evidence of rupture (PR) and intraplaque
haemorrhage (IPH) than groups2and3 (Table 2, Figs. 1 and2).
Expression of genes important in haemostasis and
correlation with histological features
Gene expression of CD68 (a macrophage specific gene) and
thrombomodulatory genes were significantly higher in the
early symptomatic group (1) compared to both late symp-
tomatic (2) and asymptomatic groups (3) (Table 3).
When analysed in relation to histological evidence of
plaque instability, there were marked increases in gene
expression for TM, t-PA and PAI-1 associated with plaque
rupture, and TF, TFPI, TM, t-PA and u-PA with intraplaque
haemorrhage (Table 4). Only TF, t-PA and PAI-1 in
Figure 1 Representative section through a carotid plaque
demonstrating evidence of plaque rupture.
Table 3 Plaque thrombomodulatory factor mRNA
concentrations (2DCt) demonstrated as median (inter-
quartile range); analysed using KruskaleWallis ANOVA
Symptom Groups
Relative
Conc
(2DCt)
Early
Symptomatic
1 (nZ 12)
Late
Symptomatic
2 (nZ 17)
Asymptomatic
3 (nZ 11)
p
value
t-PA 316 21 32 0.019
(32.94e709) (6.3e34.7) (18.22e150)
u-PA 97 17 21 0.061
(27.5e658.6) (7.37e37) (10e162)
PAI-1 874 37 59 0.028
(208e1763) (22.24e80) (14.2e1008)
TF 65 4 12 0.018
(9.4e303.7) (7.67e38.5) (9.2e29.8)
TFPI 215 8 15 0.025
(7.26e775) (1.95e22.1) (2.23e101)
TM 167 28 30 0.038
(52.8e614) (7.67e38.5) (9.2e29.8)
CD68 433 102 374 0.016
(164e3057) (40.48e246) (164e1142)
VECAD 51 6 10 0.027
(6.67e559) (0.91e12) (5.2e49.4)
Carotid Expression of Thrombomodulatory Factors 23association with IPH reached significance, though not after
correction for multiple analyses.
Discussion
The role of thrombomodulatory factors in plaque instability
is complex and the cause/effect relationship unclear. Up-
regulation may contribute to plaque instability and risk of
thrombo-embolic complications. During the transient
period of plaque instability, there is increased inflammation
and proteolysis within the lesion which may be influenced,
at least in part, by up-regulation of thrombomodulatory
factors. Acute plaque disruption itself then leads to further
activation of the coagulation cascade and thrombus
formation, which accounts for the majority of subsequent
adverse clinical sequelae. Intraplaque haemorrhage will
also directly affect the expression of thrombomodulatory
factors. Conversely, thrombomodulatory factors also influ-
ence smooth muscle proliferation and migration which is
important in the healing process leading into a quiescent
phase following the period of instability.
The expression of thrombomodulatory factors has been
investigated in unstable coronary and other plaques,3,5,7e9
but the relationship in carotid plaques is less well docu-
mented with no published reports regarding temporalFigure 2 Representative section through a carotid plaque
demonstrating evidence of intraplaque haemorrhage.expression related to clinical ischaemic events. The aim of
this study was to investigate changes in gene expression
after the onset of clinical ischaemic events.
In agreement with previous work,10 we have demon-
strated an increased incidence in plaque rupture, intra-
plaque haemorrhage in patients with recent symptoms.
Concurrent with this, we have demonstrated that expres-
sion of thrombomodulatory genes is elevated following
a clinical event, but that within one month levels of
expression are indistinguishable from asymptomatic
patients.
This is clearly a complex interrelationship, and may well
simply reflect a generalised up-regulation of factors asso-
ciated with a disturbed mechanism around the time of
plaque destabilisation. The ‘chicken-and-egg’ question is
a difficult one and certainly further work is required to
establish the role of individual factors, and the ratios of
pro- and anti-thrombotic factors. Further more detailed
temporal studies would be helpful, though are clinically
difficult.
In this study we have demonstrated a marked transient
increase in plaque TF and TFPI expression in association
with other thrombomodulatory factors. Tissue factor has
been suggested as a candidate molecule for the link
between plaque inflammation, instability and thrombo-
embolic phenomena.11 Tissue factor pathway inhibitor is
the major down-regulator of the procoagulant activity of
the TF-factor V11a complex.12 Previous studies have
demonstrated increased expression of tissue factor at sites
of carotid4 and coronary plaque inflammation.13 The level
of tissue factor in coronary plaques form patients with
unstable angina is more than twice the level in plaques
from patients with stable angina.13 Similarly, TFPI expres-
sion is up-regulated in plaques, and is expressed by
Table 4 Gene expression associated with histological features of plaque instability, namely plaque rupture (PR) and intra-
plaque haemorrhage (IPH). TF, t-PA and PAI-1 in association with IPH reached significance, though not after correction for
multiple analyses
PR (þ) PR () p IPH (þ) IPH () p
TF 13 (4e120) 12 (5e28) 0.70 63 (10e184) 8 (4e21) 0.04
TFPI 15 (8e403) 15 (5e53) 0.47 188 (9e780) 11 (2e33) 0.08
TM 60 (8e220) 36 (22e60) 0.93 140 (10e544) 29 (11e45) 0.14
t-PA 129 (15e490) 34 (14e99) 0.51 237 (24e614) 27 (10e94) 0.04
u-PA 35 (12e335) 29 (16e88) 0.84 71 (21e650) 21 (10e70) 0.12
PAI-1 361 (40e1214) 44 (26e568) 0.37 690 (54e1720) 40 (21e208) 0.04
VECAD 9 (7e71) 8 (3e15) 0.55 11 (7e318) 8 (2e13) 0.16
CD68 191 (120e449) 241 (37e669) 0.97 210 (120e1155) 189 (69e473) 0.55
24 S. Sayed et al.a variety of cell types including macrophages and smooth
muscle cells.14 Studies investigating plaque proteolysis
have demonstrated a very similar transient up-regulation in
matrix metalloproteinase gene expression which returns to
normal levels within 1 month of symptoms.15,16
Levels of t-PA and u-PA have been demonstrated to be
elevated in advanced atherosclerosis and localised to areas
in the fibrous cap populated by macrophages, and areas
lateral to the cap populated by migrating smooth muscle
cells.5,6 Inhibition of the fibrinolytic system occurs through
PAI-1, which is also up-regulated in atherosclerosis
compared to normal tissue.7 The exact role of PAI-1 and
t-PA in the atherosclerotic lesion is unknown though is likely
to be multi-factorial.
One potential criticism of this study is stratification
according to symptom-free duration. As with previous
studies, histological evidence of instability in terms of
plaque rupture and intraplaque haemorrhage was identified
more frequently in recently symptomatic plaques.
However, these features do occur in all symptom groups.
Previous studies have identified coronary plaque disruption
at post-mortem examination in patients who died of non-
cardiac causes, suggesting that acute plaque disruption can
occur without causing symptoms. However, much recent
data relating to plaque instability, particularly with refer-
ence to histological changes, proteolysis and inflammation
reinforce the hypothesis that some plaque destabilisation is
transient, and the return to a stable plaque within 4 weeks
mirrors the reduction in clinical susceptibility to further
neurological thrombo-embolic events.
In addition, we have focused on gene expression levels
as these were likely to be more reflective of the transient
nature of change associated with plaque instability. We
recognise that absolute abundance at a protein level and
cell localisation may not provide the same correlation with
histological features of the lesions, nor symptomatology.
We were limited in this study by the quantity of tissue
available, and further work is underway to examine protein
levels and ratios between pro- and anti-thrombotic factors.
When gene expression levels were compared with
histological features of instability, there were marked
differences, particularly with evidence of intraplaque
haemorrhage. However, with correction for multiple anal-
yses, these failed to reach statistical significance. This is
almost certainly a reflection of cohort numbers, and further
work is required to examine this relationship in more detail.Conclusion
This study demonstrates that gene expression for a number
of thrombomodulatory factors is elevated in acute symp-
tomatic plaques. This is the first time a clear temporal
differential expression of thrombomodulatory genes
following a clinical event, attributable to a significant
carotid stenosis, had been identified. The precise roles of
these individual factors remain unclear and further work is
required to elucidate the effects of imbalances within the
procoagulant and fibrinolytic systems in unstable plaques.17
Our data identify a dynamic homeostatic mechanism
which may contribute to plaque instability. Furthermore,
circulating thrombomodulatory factors may be potential
surrogates for evaluating the efficacy of new pharmaco-
therapeutic agents for plaque stabilisation.
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